
What is claimed is:

1. A compound of Formula I:



(I)

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof, wherein:

X is C(=O) or CH_2;

Y is O, cyanamido (N–≡N), or amido (NH);

m is an integer of 0, 1, 2, or 3;

R^1 is hydrogen or C_{1-6} alkyl;

R^2 is hydrogen, $–NO_2$, C_{1-10} alkyl, C_{0-6} alkyl-(5 to 10 membered heteroaryl), C_{0-6} alkyl-(5 to 6 membered heterocyclyl), C_{0-6} alkyl-OH, C_{0-4} alkyl-NH_2, $–NHCO-C_{1-6}$ alkyl, $–OR^{21}$, or $–(CH_2-Z)_{0-2}$-(5 to 10 membered heteroaryl), where each heteroaryl and heterocyclyl is optionally substituted with one or more C_{1-6} alkyl;

R^3 is hydrogen, halogen, $–NO_2$, C_{0-6} alkyl-(5 to 10 membered heteroaryl), C_{0-6} alkyl-(5 to 6 membered heterocyclyl), C_{0-6} alkyl-OH, C_{0-4} alkyl-NH_2, $–NHCO-C_{1-6}$ alkyl, $–OR^{21}$, or $–(CH_2-Z)_{0-2}$-(5 to 10 membered heteroaryl), where each heteroaryl and heterocyclyl is optionally substituted with one or more C_{1-6} alkyl;

R^{21} is C_{6-10} aryl, 5 to 10 membered heteroaryl, 5 to 6 membered heterocyclyl, or $–CO(CH_2)_{0-2}R^{22}$, wherein the aryl, heteroaryl, and heterocyclyl are each optionally substituted with one or more C_{1-6} alkyl;

R^{22} is $–NH_2$ or 5 to 6 membered heterocyclyl; and

Z is CH_2, NH, or O;

with the proviso that when R^1 is hydrogen, then R^2 is not hydrogen or C_{1-10} alkyl;

with the proviso that when Y is O, then R^3 is not halogen; and

with the proviso that when Y is O and R^3 is halogen, then R^2 is C_{0-6} alkyl-(5-6 membered heterocyclyl).













2. The compound of claim 1, wherein R^1 is hydrogen or methyl.


3. The compound of claim 1 or 2, wherein R^2 is hydrogen, amino, acetamido, hydroxy, nitro, aminomethyl, hydroxymethyl, 2-methyl-1*H*-imidazol-1-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 4-methylpiperazin-1-yl)methyl, 2-methyl-2*H*-pyrazol-3-yl, 1-methyl-1*H*-pyrazol-3-yl, 2-methylthiazol-4-yl, 4-methyl-4*H*-1,2,4-triazol-3-yl, morpholinomethyl, (pyridin-4-yl)methyl, (pyridin-4-

yloxy)methyl, pheoxy, pyridin-2-yloxy, piperidin-4-yloxy, 2-aminoacetoxy, or 2-piperazin-1-ylacetoxy.


4. The compound of any of claims 1 to 3, wherein R^3 is hydrogen, amino, acetamido, hydroxy, nitro, aminomethyl, hydroxymethyl, 2-methyl-1*H*-imidazol-1-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 4-methylpiperazin-1-yl)methyl, 2-methyl-2*H*-pyrazol-3-yl, 1-methyl-1*H*-pyrazol-3-yl, 2-methylthiazol-4-yl, 4-methyl-4*H*-1,2,4-triazol-3-yl, morpholinomethyl, (pyridin-4-yl)methyl, (pyridin-4-yloxy)methyl, pheoxy, pyridin-2-yloxy, piperidin-4-yloxy, 2-aminoacetoxy, or 2-piperazin-1-ylacetoxy.

5. The compound of claim 1, which is:



,

,

,

,

,

,

,

,

,

,

,

,




,




,




,




,




,




,




,




,




,




,




,




,




,














,




,



,


,

,

,

,

,

,

,

,

,

,

,
or a pharmaceutically acceptable salt, solvate, prodrug, and stereoisomer thereof.

6. A compound of Formula II:



(II)

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof, wherein:

X is C(=O) or CH_2;









m is an integer of 0, 1, 2, or 3;


R^4 is C_{3-10} cycloalkyl, 5 to 10 membered heterocyclyl, 5 to 10 membered heteroaryl, or C_{0-4} alkyl-$NR^{41}R^{42}$; wherein the cycloalkyl, heterocyclyl, and heteroaryl are each optionally substituted with one or more halogen, C_{1-6} alkyl, -CO-$NR^{43}R^{44}$, -$COOR^{45}$, or C_{0-4} alkyl-C_{6-10} aryl, wherein the aryl itself may be optionally substituted with one or more halogen; and


R^{41}, R^{42}, R^{43}, R^{44}, and R^{45} are each independently hydrogen or C_{1-6} alkyl.


7. The compound of claim 6, wherein R^4 is 3-(*N,N*-diethylamino)propyl, 4-acetamidophenyl, 3-(2-aminoacetoxy)-4-methylphenyl, 3-aminomethyl-4-methylphenyl, 2-aminomethyl-5-methylphenyl, 3-aminophenyl, 3-amino-4-methylphenyl, 3-chloro-4-methylphenyl, 4-hydroxymethylphenyl, 3-hydroxy-4-methylphenyl, 3-(2-methyl-1*H*-imidazol-1-yl)phenyl, 4-methyl-3-nitrophenyl, 3-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl, 4-methyl-3-(2-piperazin-1-ylacetoxy)-phenyl, 3-((4-methylpiperazin-1-yl)methyl)phenyl, 3-(1-methyl-1*H*-pyrazol-3-yl)phenyl, 3-(2-methyl-2*H*-pyrazol-3-yl)phenyl, 3-(2-methylthiazol-4-yl)phenyl, 4-(4-methyl-4*H*-1,2,4-triazol-3-yl)phenyl, 3-(morpholinomethyl)phenyl, 4-(morpholinomethyl)phenyl, 4-nitrophenyl, phenyl, 3-(piperidin-4-yloxy)phenyl, 4-(pyridin-4-yl)methylphenyl, 4-((pyridin-4-yloxy)methyl)phenyl, 3-(pyridin-2-yloxy)phenyl, 3-phenoxyphenyl, 4-*tert*-butylcyclohexyl, *cis*-4-*tert*-butylcyclohexyl, *trans*-4-*tert*-butylcyclohexyl, 4-methylcyclohexyl, *cis*-4-methylcyclohexyl, *trans*-4-methylcyclohexyl, 1-benzylpiperidin-4-yl, 4-methyltetrahydro-2*H*-pyran-4-yl, piperidin-4-yl, 4-phenylcyclohexyl, *cis*-4-phenylcyclohexyl, or *trans*-4-phenylcyclohexyl.

8. The compound of claim 6, which is:


,

,

,

,

,

,

,

,








or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof.

9. A compound of Formula III:



(III)

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof, wherein:

X is C(=O) or CH_2;

m is an integer of 0, 1, 2, or 3;

R^5 and R^6 are each independently: hydrogen, halo, C_{1-6} alkyl, oxo, $-NO_2$, C_{1-6} alkoxy, -Z-C_{1-6} alkyl, , C_{0-6} alkyl-(5 to 10 membered heteroaryl), C_{0-6} alkyl-(5 to 6 membered heterocyclyl), C_{0-6} alkyl-OH, C_{0-4} alkyl-NH_2, –NHCO-C_{1-6} alkyl, $–OR^{21}$, or $–(CH_2\text{-}Y)_{0-2}$-(5 to 10 membered heteroaryl),

wherein Z is S or SO_2;

wherein R^{21} is as defined above;

wherein each heteroaryl and heterocyclyl above is optionally substituted with one or more C_{1-6} alkyl; and

wherein the alkyl or alkoxy above may be optionally substituted with one or more: halogen; cyano; nitro; amino; C_{1-6} alkylidenedioxy; C_{1-6} alkoxy, itself optionally substituted with one or more halogens; or C_{1-6} alkylthio, itself optionally substituted with one or more halogens;

R^7 is $–COR^{71}$ or $–PO(OR^{72})(OR^{73})$;


R^{71} is C_{1-10} alkyl, C_{6-10} aryl, or 5 to 6 membered heterocyclyl; wherein the alkyl, aryl, heterocyclyl may be optionally substituted with one or more amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, or $–COOR^{74}$; and


R^{72}, R^{73}, and R^{74} are ach independently hydrogen or C_{1-10} alkyl.


10. The compound of claim 9, wherein R^5 is fluoro or chloro.


11. The compound of claim 9 or 10, wherein R^6 is fluoro or chloro.


12. The compound of claim 9, which is:



,



,



,



,



,



,



,




,


,


,



,


,


,

,

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof.

13. A compound of Formula IV:



(IV)

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof, wherein:

X is C(=O) or CH_2;

n is an integer of 0 or 1;





R^8 is hydrogen or halo; and

R^9 is hydrogen, amino, or 5 to 10 membered heteroaryl or heterocyclyl;

with the proviso that when m is 0, R^9 is not hydrogen.


14. The compound of claim 13, wherein n is 1.

15. The compound of claim 13, which is:


,

,

,

,

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof.

16. A compound of Formula V:



(V)













or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof, wherein:









X is C(=O) or CH_2;

m is an integer of 0, 1, 2, or 3;

R^{10} and R^{11} are each independently hydrogen, halo, C_{1-6} alkyl, or C_{6-10} aryloxy, wherein the alkyl and aryl are each optionally substituted with one or more halo.


17. The compound of claim 16, which is:

,
,
,
,
,
,
,
,
,
,
,
,


,

,

,

,

,

,

,

,

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof.

18. A compound of Formula (VI):


,

(VI)

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof, wherein:

X is CH_2 or C=O

















m and n are each independently 0 or 1;
















p is 0, 1, 2, or 3;

R^{81} is 5 to 6 membered heterocyclyl, optionally substituted with C_{1-6} alkyl; and











R^{82} is hydrogen or halogen.

19. The compound of claim 18, which is:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,








,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof.

20. A compound of the following formula:


,

,

,

,

,

,

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof.

21. A pharmaceutical composition comprising the compound of any of claims 1 to 20, and one or more pharmaceutically acceptable excipients or carriers.

22. The pharmaceutical composition of claim 21, further comprising a second therapeutic agent.

23. The pharmaceutical composition of claim 21 or 22, wherein the composition is formulated for single dose administration.

24. The pharmaceutical composition of any of claims 21 to 23, wherein the composition is formulated as oral, parenteral, or intravenous dosage form.

25. The pharmaceutical composition of claim 24, wherein the oral dosage form is a tablet or capsule.

26. A method of treating, managing, or preventing a disease or disorder which comprises administering to a subject a therapeutically effective amount of a compound of any of claims 1 to 20, wherein the disease or disorder is cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, hemoglobinopathy or a related disorder, or a TNFα related disorder.

27. The method of claim 26, wherein the disease is cancer.


28. The method of claim 27, wherein the cancer is hematologic or solid cancer.

29. The method of any of claims 26 to 28, which further comprises administration of one or more additional active agents.

30. The method of any of claims 26 to 29, wherein the compound is administered orally or parenterally.

What is claimed is:

1. A compound of Formula II:



(II)

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof, wherein:

X is C(=O) or CH_2;

m is an integer of 0, 1, 2, or 3;












R^4 is C_{3-10} cycloalkyl, 5 to 10 membered heterocyclyl, 5 to 10 membered heteroaryl, or C_{0-4} alkyl-$NR^{41}R^{42}$; wherein the cycloalkyl, heterocyclyl, and heteroaryl are each optionally substituted with one or more halogen, C_{1-6} alkyl, -CO-$NR^{43}R^{44}$, -$COOR^{45}$, or C_{0-4} alkyl-C_{6-10} aryl, wherein the aryl itself may be optionally substituted with one or more halogen; and

R^{41}, R^{42}, R^{43}, R^{44}, and R^{45} are each independently hydrogen or C_{1-6} alkyl.

2. The compound of claim 1, wherein R^4 is 3-(N,N-diethylamino)propyl, 4-tert-butylcyclohexyl, cis-4-tert-butylcyclohexyl, *trans-4-tert*butylcyclohexyl, 4-methylcyclohexyl, cis-4-methylcyclohexyl, trans-4-methylcyclohexyl, 1-benzylpiperidin-4-yl, 4-methyltetrahydro-2H-pyran-4-yl, piperidin-4-yl, 4-phenylcyclohexyl, *cis-4-*


phenylcyclohexyl, or *trans*-4-phenylcyclohexyl.

3. The compound of claim 1, which is:


,

,

,

,

,

,

,

,

,

,

,

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof.

4. A compound of Formula III:



(III)

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof, wherein:

X is C(=O) or CH_2;

m is an integer of 0, 1, 2, or 3;

R^5 and R^6 are each independently: hydrogen, halo, C_{1-6} alkyl, oxo, $-NO_2$, C_{1-6} alkoxy, -Z-C_{1-6} alkyl, , C_{0-6} alkyl-(5 to 10 membered heteroaryl), C_{0-6} alkyl-(5 to 6 membered heterocyclyl), C_{0-6} alkyl-OH, C_{0-4} alkyl-NH_2, –NHCO-C_{1-6} alkyl, $-OR^{21}$, or $-(CH_2\text{-}Y)_{0-2}$-(5 to 10 membered heteroaryl),

wherein Z is S or SO_2;

wherein R^{21} is as defined above;

wherein each heteroaryl and heterocyclyl above is optionally substituted with one or more C_{1-6} alkyl; and wherein the alkyl or alkoxy above may be optionally substituted with one or more: halogen; cyano; nitro; amino; C_{1-6} alkylidenedioxy; C_{1-6} alkoxy, itself optionally substituted with one or more halogens; or C_{1-6} alkylthio, itself optionally substituted with one or more halogens;

R^7 is $-COR^{71}$ or $-PO(OR^{72})(OR^{73})$;











R^{71} is C_{1-10} alkyl, C_{6-10} aryl, or 5 to 6 membered heterocyclyl; wherein the alkyl, aryl, heterocyclyl may be optionally substituted with one or more amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, or $-COOR^{74}$; and





R^{72}, R^{73}, and R^{74} are ach independently hydrogen or C_{1-10} alkyl.

5. The compound of claim 4, wherein R^5 is fluoro or chloro.

6. The compound of claim 4 or 5, wherein R^6 is fluoro or chloro.


7. The compound of claim 4, which is:


,

,

,

,

,

,

,

,

,

,


,

,

,

,

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof.

8. A compound of Formula IV:



(IV)

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof, wherein:

X is C(=O) or CH_2;

n is an integer of 0 or 1;



R^8 is hydrogen or halo; and



R^9 is hydrogen, amino, or 5 to 10 membered heteroaryl or heterocyclyl;

with the proviso that when m is 0, R^9 is not hydrogen.

9. The compound of claim 8, wherein n is 1.


10. The compound of claim 8, which is:


,

,


,

,

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof.

11. A compound of Formula V:



(V)





or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof, wherein:















X is C(=O) or CH_2;

m is an integer of 0, 1, 2, or 3;

R^{10} and R^{11} are each independently hydrogen, halo, C_{1-6} alkyl, or C_{6-10} aryloxy, wherein the alkyl and aryl are each optionally substituted with one or more halo.



12. The compound of claim 11, which is:


,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof.

13. A compound of Formula (VI):



(VI)

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof, wherein:

X is CH_2 or C=O





m and n are each independently 0 or 1;















p is 0, 1, 2, or 3;

R^{81} is 5 to 6 membered heterocyclyl, optionally substituted with C_{1-6} alkyl; and

R^{82} is hydrogen or halogen.













14. The compound of claim 13, which is:

















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,





,



,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof.

15. A compound of the following formula:


,

,

,

,





or a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer thereof.

16. A pharmaceutical composition comprising the compound of any of claims 1 to 15, and one or more pharmaceutically acceptable excipients or carriers.

17. The pharmaceutical composition of claim 16, further comprising a second therapeutic agent.

18. The pharmaceutical composition of claim 16 or 17, wherein the composition is formulated for single dose administration.

19. The pharmaceutical composition of any of claims 16 to 18, wherein the composition is formulated as oral, parenteral, or intravenous dosage form.

20. The pharmaceutical composition of claim 19, wherein the oral dosage form is a tablet or capsule.

21. A method of treating, managing, or preventing a disease or disorder which comprises administering to a subject a therapeutically effective amount of a compound of any of claims 1 to 15, wherein the disease or disorder is cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, hemoglobinopathy or a related disorder, or a TNFα related disorder.

22. The method of claim 21, wherein the disease is cancer.

23. The method of claim 22, wherein the cancer is hematologic or solid cancer.

24. The method of any of claims 21 to 23, which further comprises administration of one or more additional active agents.

25. The method of any of claims 21 to 24, wherein the compound is administered orally or parenterally.